Biote reports record FY2022 revenue $165M, Q4 adj EBITDA up 40%; guides FY2023 rev $190-200M

biote Corp.

Q4 revenue $44.5M (+18.5%), net income $12.8M, diluted EPS $0.18; adjusted EBITDA $13.1M (+40%).
FY2022 revenue $165.0M (+18.3%), net income $1.3M, diluted EPS loss ($0.12); adjusted EBITDA $50.1M (+24.6%).
2023 guidance: revenue $190-200M, adjusted EBITDA $56-60M; expects stronger H2 performance.
Completed secondary offering in Jan 2023 to increase trading liquidity and broaden institutional ownership.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

biote Corp. reported the fourth quarter ended December 31, 2022 results: revenue $44.5 million, net income $12.8 million, EPS $0.18.

Period: the fourth quarter ended December 31, 2022
Revenue: $44.5 million
Net income: $12.8 million
EPS: $0.18
Result: reported results

Exact text from the filing

Fourth Quarter Highlights, year over year : • Revenue of $44.5 million, an 18.5% increase. • Net income of $12.8 million and fully diluted GAAP earnings per share of $0.18.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

biote Corp. reported 2023 results: revenue $190-200 million. Guidance initiated.

Period: 2023
Revenue: $190-200 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

biote Corp. reported the fiscal year ended December 31, 2022 results: revenue $165.0 million, net income $1.3 million, EPS $(0.12).

Period: the fiscal year ended December 31, 2022
Revenue: $165.0 million
Net income: $1.3 million
EPS: $(0.12)
Result: reported results

Exact text from the filing

Full Year 2022 Highlights, year over year: • Revenue of $165.0 million, an 18.3% increase. • Net income of $1.3 million and fully diluted GAAP loss per share of $(0.12).

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-23-082331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.